Home > Haematology > EHA 2021 > Leukaemia > Oral azacitidine improves overall survival in patients with acute myeloid leukaemia

Oral azacitidine improves overall survival in patients with acute myeloid leukaemia

Presented By
Prof. Hartmut Döhner, Universitätsklinikum Ulm, Germany
Conference
EHA 2021
Trial
Phase 2, QUAZAR AML-001
Updated results of the QUAZAR AML-001 trial showed an overall survival (OS) benefit of treatment with oral azacitidine compared with placebo in acute myeloid leukaemia (AML). This improvement was irrespective of the patients’ mutational status, however, NPM1 and FLT3 mutations were prognostic and predictive of a survival benefit. Characterisation of NPM1mut (23–30%) with and without concomitant internal tandem duplications in FLT3 (FLT3-ITD) (approximately 25%) are used to ascribe risk categories in patients with AML [1,2]. In the multicentre, placebo-controlled, randomised, phase 3 QUAZAR AML-001 trial (NCT01757535), oral azacitidine (CC-486) maintenance therapy significantly prolonged OS and relapse-free survival (RFS) compared with placebo [3]. Prof. Hartmut Döhner...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on